# Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

> **NCT00060489** · PHASE3 · COMPLETED · sponsor: **AstraZeneca**

## Conditions studied

- Bipolar Disorder
- Depression, Bipolar

## Interventions

- **DRUG:** SEROQUEL (quetiapine fumarate) Tablets

## Key facts

- **NCT ID:** NCT00060489
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** — (—)
- **Last updated:** 2011-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00060489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00060489, "Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00060489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*